Professor C. Current therapies do not prevent the development of disability in such sufferers . The ADAGIO research, which used a novel trial style with three primary endpoints, shows that the drug includes a positive effect on slowing the progression of patients’ disability, beyond its already known symptomatic advantage. As talked about in THE BRAND NEW England Journal of Medication article, it is possible that a greater symptomatic aftereffect of the 2mg/day dose may have masked an advantage associated with early-begin treatment in the populace of patients with extremely mild disease included in the ADAGIO study. A post-hoc analysis conducted on a sub-group of sufferers with highest baseline UPDRS showed excellent results with the 2mg/day dose, supporting this hypothesis.